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The helper  and suppressor  regulatory activities  exerted on antibody responses 
by T lymphocytes are associated with subregions of  the  I region of  the murine 
H.2  (major histocompatibility) complex. Using antisera defining Ia antigens, 
raised by immunization  between  congenic pairs of mice differing at the ! 
region, specific  suppressor T cells  (1, 2) and their soluble  and mediators (3-5) 
have been shown to bear I-J subregion coded determinants, whereas certain 
helper (enhancing) factors  and possibly helper cells  possess  I-A coded determi- 
nants (6, 7).i  Analysis of  the effects  of  such specific  anti-Ia  antisera on immune 
responses can, therefore,  provide information concerning the regulatory func- 
tions of  the various  ! region products, This approach has been used in various 
model systems, and several investigators  have reported marked inhibition  of  in 
vitro lymphocyte reactivity by distinct anti-la  antisera  (8-12). It was thus 
appropriate  to determine  whether  such antisera  would  also alter in vivo 
immune  responses.  We  reported  recently  (13) that microliter amounts  of 
alloantisera against I  k and I  # gene products were able to potentiate primary 
IgM  and  IgG in vivo  plaque-forming  cell (PFC)  2 responses  to suboptimal 
immunogenic  doses of sheep erythrocytes  (SRBC) in A/J and BALB/c mice, 
respectively. The same immunopotentiating  activity was observed with an 
anti-I-J  k  antiserum in A/J mice. Further studies revealed that in vivo adminis- 
tration of  the same anti-I-J  k antiserum decreases tumor growth in A/J mice 
inoculated  with a syngeneic methylcholanthrene-induced  fibrosarcoma  (14), 
known to elicit  potent suppressor T-cell responses active in inhibiting anti- 
tumor immunity  (15, 16).  These observations  raised the possibility  that the 
potentiation of SRBC  PFC  responses observed with the anti-I-J  k antiserum, 
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and with the anti-I-J containing whole anti-I region antisera,  could be attrib- 
uted to an in vivo interference with the I-J-positive components (cells and/or 
factors) of an antigen-specific suppressor system. 
The  present  investigation  has  been  designed  to  test  directly  the  possible 
action  of anti-I-J  antisera  on  the  well-defined T-ceU-dependent  suppression 
characterizing the  responses  of certain  nonresponder strains  of mice to  the 
copelymers L-glutamic acid  6°,  L-alanine  3°,  L-tyrosine  1°  (GAT)  and  L-glutamic 
acid  5°, L-tyrosine  5° (GT), which have been extensively studied in this laboratory. 
The  specific  immune  suppression  in  these  systems  can  be  summarized  as 
follows (17). Nonresponder mice bearing the 1"1-2 q.s haplotypes immunized with 
GAT develop specific suppressor T cells which suppress GAT-MBSA responses 
(18).  Similarly,  specific suppression  of GT-MBSA  responses  can be  detected 
after GT administration to nonresponder mice bearing the 1-1-2 k.~,s.f haplotypes 
(19). In both cases, antigen-specific suppression can be transferred into normal 
syngeneic recipients by T-derived lymphocytes from such GAT or GT primed, 
unresponsive mice. 
We report in this paper that in vivo treatment with anti-I-J  s and anti-LJ  k 
antisera: (a) potentiates the primary in vivo PFC response to suboptimal doses 
of SRBC  in SJL and A/J mice; (b)  induces direct responsiveness to  GAT and 
GT  in  nonrespender  suppressor  SJL  and  CBA  mice,  respectively;  and  (c) 
prevents  in  these  mice the development of detectable  GAT  and  GT-specific 
suppressor T cells, as assayed by adoptive transfer experiments. The implica- 
tions  of  these  findings  are  discussed  in  regard  to  our  knowledge  of the 
suppressive mechanisms active in these systems. 
Materials and Methods 
Mice.  SJL  (H-2  m) and CBA  (H-2  k) mice were purchased from The Jackson Laboratory,  Bar 
Harbor,  Maine and used throughout this study at 8-12 wk of age.  They were maintained in our 
animal facilities on standard laboratory chow and acidified chlorinated water ad lib. Either male 
or female were used, but all mice were age and sex matched in a single experiment. 
Antisera.  The antisera used in this study were raised in mice from our breeding colony by 
repeated  intraperitoneal  inoculation  of the  appropriate  lymphoid  cells.  The  following  strain 
combinations were  used:  (a)  anti-I-J  k,  B10.A(3R)  anti-B10.A(5R);  (b)  anti-I-J",  [B10.A(3R)  x 
B10.S(9R)]F1  anti-B10.HTT.  As a  result of the strain combinations used to produce  the latter 
serum, it may contain contaminating antibodies directed to the I-C  k, S k, and G k gene products, 
although such antibodies have not been observed. The cytetexic titer of these sera by standard 
dye exclusion against donor spleen cells was <1/10. 
Antigens.  Sheep blood in Alsever's solution was purchased from Grand Island Biological Co., 
(Grand  Island,  N.  Y.).  Before  using,  the  SRBC  were  washed  three  times  in  sterile  Hanks' 
balanced salt solution (HBSS), the buffy coat being removed after the first centrifugation. The 
random linear copolymer GAT,  average  tool  wt  38,000  and GT,  average  tool  wt  32,000  were 
purchased from Miles Laboratories Inc.,  Miles Research Products,  Elkhart, Ind.  Stock solutions 
(10 mg/ml) were prepared in saline containing 1% NaCO3 at pH 9.0-9.5.  Methylated bovine 
serum albumin (MBSA) was purchased from Calbiochem, San Diego, Calif.  The copelymers GT 
and GAT were complexed to MBSA  as previously  described  (20,  21). 
Immunizations.  SRBC, adjusted to the appropriate concentrations  in 0.5 ml of  HBSS, were 
mixed with various amounts of  alloantisera  and injected  in the lateral  tail  vein of  mice. Control 
groups received the same inoculum containing SRBC alone.  Mice were immunized either  with 
100 ~g GT, 10 ~g GT as GT-MBSA, 10 ~g GAT or 10 ~g GAT as GAT-MBSA  intraperitoneally 
(i.p.)  in a vol of  0.2 ml. The adjuvants were either  a 5% solution  of  magnesium and aluminum 
hydroxides (Maalox, William H. Rorer,  Inc.,  Fort Washington, Pa.)  or a mixture of  Maalox (5%) 
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Antiserum  Treatment.  10  /~l of the appropriate antiserum was diluted in 0.25  ml of HBSS 
and injected intravenously into mice immediately after immunization with the copolymer.  The 
same treatment was repeated the 2 following days.  Control groups received either 10  /~1 of an 
irrelevant antiserum or 10/~1 of HBSS alone in the same manner. 
Adoptive Transfer.  Mice were primed on day 0 either with GAT or GT in Maalox,  or with 
Maalox (5%) alone. They received three daily intravenous (i.v.) injections of 10 pl of antiserum 
diluted in HBSS  (days 0,  1,  and 2).  3 days after the priming, the mice were sacrificed and the 
spleens were teased in sterile HBSS.  The spleen cells were washed twice in HBSS and adjusted 
to 40  x  10  e viable cells per ml.  10  ×  10  e primed cells were injected intravenously into normal 
recipients which were immediately challenged with GAT-MBSA or GT-MBSA in M/P i.p. at the 
doses detailed above. 
PFC Assay.  The anti-SRBC IgM and IgG were enumerated 6 days aider immunization by a 
modification of the Jerne hemolytic plaque technique (22).  A  goat anti-  F  antiserum (the gift of 
R. Asofsky,  the National Institutes of Health) was used to inhibit IgM PFC,  and a  rabbit anti- 
mouse IgG was used to develop IgG PFC.  The antibody responses to GAT,  GT,  GAT-MBSA, or 
GT-MBSA were assayed 7 days after immunization, using GAT-ceated SRBC,  which detect the 
highly  cross-reactive  anti-GT  antibodies  as  well  (20).  All  results  are  expressed  as  PFC  per 
spleen. The cell recovery per spleen did not vary significantly between groups. 
Statistical Analysis.  All data were analysed for significance by using a  two-tailed Student's t 
test, performed on a  Wang 700 calculator. 
Results 
Potentiation of the Primary In Vivo Response to SRBC by Anti-I-J Alloanti- 
sera in SJL and A/J Mice.  We previously reported that a  [B10.A(3R)  × DBA/ 
2]F1 anti-B10.A(5R) antiserum (anti-I-J  k) was able to potentiate the IgM and 
IgG primary PFC  responses  to suboptimal doses of SRBC  in  A/J  mice  (13). 
Experiments were designed to verify that the same potentiation could also be 
observed in the same strain using another anti-I-J  k antiserum. A/J mice were 
immunized with 3.5  ×  105 SRBC alone or with the same dose of SRBC mixed 
with  1  ~tl  of  [B10.A(3R)  anti-B10.A(5R)]  antiserum  (anti-I-Jk).  A  twofold 
increase in the IgM and IgG PFC responses  (groups V and VI,  Table I) was 
observed in the group receiving the antiserum treatment. Thus, two different 
anti-I-J  k antisera share  the same  immunopotentiating activity on  SRBC  re- 
sponses in A/J mice. In preliminary titration experiments in SJL mice, 2 ×  108 
SRBC  were  found to  be  the  antigen dose  giving a  response just  above  the 
background. Groups of mice were then immunized with this number of SRBC 
together with 5 or 10/~l of anti-I-J  s antiserum, and the PFC responses on day 6 
were compared to those of the control groups receiving 2  ×  10  s SRBC alone. 
The results of several experiments of this type are summarized on the top of 
Table  I.  5  or  10  /~1  of anti-I-J  ~ antiserum  induced  a  significant  (twofold) 
increase of both IgM and IgG responses, whereas no significant increase was 
observed with 10  F1  of normal mouse serum.  It can be concluded, therefore, 
that this potentiating activity on SRBC responses is a common property of both 
anti-I-J  k and anti-I-J  s antisera. 
Responsiveness  to  GT  in  "Suppressor"  CBA  Mice after In  Vivo  Treatment 
with an Anti-I-J  k Antiserum.  The nonresponder status to GT in suppressor 
strains  is  related to  a  predominant specific suppression  aider  immunization 
with this antigen. This conclusion is based in large measure on the observation 
that GT suppressor mice can respond to GT after appropriate cyclophosphamide 
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T.*.m.~ I 
Effect of Anti-I-J Antisera on the Primary In Vivo Anti-SRBC Responses in A/J and 
SJL Mice 
No. of  IgM PFC per  IgG PFC per 
Group  Strain  mice per  SRBC*  Antiserums  spleen Mean ±  P§  spleen Mean ±  P§ 
group  SE  SE 
I  SJL (H-2')  14  2  x  l0  s  None  6,060 ±  483  -  2,457  ±  182  - 
II  SJL (H-2')  10  2  ×  l0  s  Anti-I-J' (10/~1)  12,280  ±  1,148  <0.001  5,315 ±  622  <0.001 
IH  SJL (H-2*)  5  2  ×  los  Anti-I-J*  (5 ~1)  13,540  +- 3,286  0.001  4,850 ±  1,387  0.01 
IV  SJL (H-2  o)  4  2  x  los  NMS~I  (10 ~l)  3,200  ±  895  NS¶  3,087  ±  37  NS 
V  A/J (H-2*)  4  3.5 x  los  None  3,050  ±  207  -  887  ±  202  - 
VI  A/J (H-2")  5  3.5 x  106  Anti-I-J  k (1 #1)  5,980  ±  919  0.02  2,540 ±  395  0.01 
* The SRBC were injected i.v. in 0.5 ml of Hanks' solution. 
Anti-I-J': [B10.A(3R) ×  B10.S(gR)]F~  anti-B10.HTT; anti-I-Jk: B10.A(3R) anti-B10.A(5R). 
§ Calculated according to the Student's t test. 
[] NMS, normal mouee serum. 
¶ NS, not significant (>0.05). 
TAnL~ II 
Effects of Anti-I-J Antisera on Primary In Vivo Responses to GT and GAT in CBA and 
SJL Mice 
Antiserum treat-  IgG Specific PFC 
No. of Mice  Immunization* 
Group  Strain  ment~ on day 0, 1,  per spleen on day  P  Value§ 
per group  (Day 0)  and 2  7 ±  SE 
I  CBA (H-2  k)  15  GT M/P  None (HBSS)  440 ±  86  - 
II  CBA (H-2  ~)  17  GT I~P  Anti-I-J  k  5,245 ±  578  <0.001 
III  CBA (H-2  k)  4  GT M/P  Anti-I-J'  525  ±  375  0.5 
IV  SJL (H-2*)  8  GAT M/P  None (HBSS)  407 ±  129  - 
V  SJL (H-2  s)  8  GAT M/P  Anti-I-J*  4,176  ±  428  <0.001 
* 100 /~g of GT or 10 ~g of GAT i.p. in M/P. 
* Anti-I-J  k antiserum: B10.A(3R) anti-B10.A(5R); anti-l-J* antiserum: [B10.A(3R) x  B10.S(9R)]F~  anti-B10.HTT. 
§ Calculated according to Student's t test. Comparisons made to groups receiving HBSS alone. 
therefore, designed to investigate whether in vivo treatment with an anti-I-J  k 
antiserum  could  induce  responsiveness in  CBA  mice.  Groups  of mice  were 
immunized  with  100  ~g  of  GT  in  M/P  i.p.  and  received  three  daffy  i.v. 
injections of 10  ~1 of either an anti-I-J  k antiserum or an I-J  s antiserum, with 
the control group receiving the same inoculum of HBSS. The results from four 
experiments  summarized  on  the  top  of Table  II  indicate  that  the  anti-I-J  k 
antiserum allows CBA mice to respond to GT. This effect appears to be specific, 
as indicated by the fact that an anti-I-J  s antiserum (which genetically cannot 
cross-react with the products of the I-J  k subregion but potentially could have 
reacted with the I-C  k, S k or G k region gene products) or an irrelevant [(B10.BR 
×  A.SW)F1 anti-SJL] antiserum (data not shown) failed to induce responsive- 
ness to GT in CBA mice. Thus, both cyclophosphamide and in vivo treatment 
with  anti-I-J  k antiserum  induce  responsiveness  to  GT  in  suppressor  nonre- 
spender strains.  These data are consistent with an inactivation of GT-specific 
suppression by the anti-I-J  k treatment. 
Nonresponder  "Suppressor"  SJL  Strain  Responds  to  GAT  after  In  Vivo 
Treatment  with  an  Anti-I-J ~ Antiserum.  The  next  series  of experiments 
investigated whether in vivo treatment with anti-I-J  ~ antiserum would lead to 
GAT responses in SJL mice. These nonresponder mice normally fail to give a 
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T-cell response. Two groups of mice were immunized with 10 ~l of GAT in M/P 
i.p.,  and  one  group  received  three  daily  injections  of 10  ~tl  of an  anti-I-J  ~ 
antiserum.  The control group received the same inoculum of HBSS alone. The 
GAT specific IgG PFC  7 days later  show  (as  for GT responses  in  CBA mice 
after  I-J  k treatment)  a  moderate  but  very significant  response  in  the  group 
treated with the anti-I-J  s serum (Table II, bottom). 
Lack of Transferrable Specific Suppression from GT-Primed CBA Mice and 
from  GAT-Primed SJL  Mice after In  Vivo  Treatment  with Anti-I-J Antise- 
rum.  The  preceding  observations  suggested  that  the  GT  and  GAT-specific 
suppressor pathways in nonresponder suppressor mice were affected by appro- 
priate anti-I-J treatment.  Previous studies revealed that complete suppression 
of GAT-MBSA or  GT-MBSA  responses  could be achieved  by transfer  of low 
numbers  of Thy  1.2-positive  spleen  cells  from  GAT  or  GT-primed  mice  into 
normal syngeneic recipients  (17).  To investigate the ability of anti-I-J antisera 
to interfere with the generation of active suppressor cells in such GAT or GT- 
primed mice, adoptive transfer experiments were performed. Mice were primed 
on  day  0,  either  with  GT  (CBA)  or  with  GAT  (SJL),  or  as  a  control,  with 
Maalox alone.  On days 0,  1, and 2,  10 ~l of the appropriate anti-I-J antiserum 
was injected intravenously into the primed mice.  The control groups received 
the  same inoculations  of HBSS alone.  3 days after priming,  10  x  106 spleen 
cells from the different groups were transferred to normal syngeneic recipients, 
which  were  immediately  challenged  with  either  GT-MBSA  (CBA)  or  GAT- 
MBSA (SJL). 7 days later,  specific IgG PFC per spleen were enumerated.  Fig. 
1  summarizes  the  results  from  several  experiments  in  CBA  mice.  10  x  106 
transferred  GT-primed cells completely suppressed the control response to GT- 
MBSA, whereas no suppression was observed with the same number of Maalox- 
primed cells or with 10  x  106 spleen cells from GT-primed  mice treated  with 
anti-I-J k antiserum.  In other experiments  (data not shown),  a  higher number 
of transferred  spleen cells was used with similar results:  20  x  106 GT-primed 
spleen cells from control mice injected only with HBSS completely suppressed 
the control response, whereas the same number of GT-primed cells from anti-I- 
Jk antiserum  treated mice did not affect the GT-MBSA response of syngeneic 
recipients.  Moreover, 20 x  106 GT-primed cells from CBA mice treated with an 
anti-I-J s  antiserum  still  suppressed  the  control  response,  further  providing 
evidence for the  specificity of the  anti-I-J  effect.  Fig.  2 summarizes  the data 
concerning the SJL mice, which showed the same pattern as CBA mice.  10  x 
106 GAT-primed spleen cells suppressed the control GAT-MBSA response, but 
this  suppression  was  no  longer  detectable with  cells from  mice treated  with 
anti-I-J s  antiserum.  These  data,  therefore,  indicate  that  3  days  after  both 
antigen  priming  and  appropriate  anti-I-J  antiserum  treatment,  the  nonre- 
sponder  suppressor  CBA  and  SJL  mice  do  not  possess  GT  or  GAT-specific 
suppressor cells detectable by standard  adoptive transfer protocols. 
Discussion 
The data reported here provide further evidence for potent in vivo effects of 
anti-I-J antisera on immune responses. First, the immunopotentiating  activity 
of [B10.A(3R)  x  DBA/2]F1 anti-B10.A(SR) antiserum  (anti-I-J k) on the primary 
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FIG.  1.  In vivo effects of anti-I-J  k antiserum on the transfer of GT-specific suppression in 
CBA (H-2  k) mice. Groups of mice (three mice per group) were primed on day 0 with 100/~g of 
GT in Maalox, or with Maalox alone, i.p. Group III received on days 0, 1, and 2, 0.25 ml of 
HBSS i.v.,  and group IV received in the same manner 10 ~1 of B10.A(3R) anti-B10.A(5R) 
antiserum (anti-I-J  k) diluted in 0.25  ml of HBSS.  On day 3,  10  x  10  e viable spleen cells 
from each group were transferred i.v. into normal recipients (four per group) which were 
immediately challenged with  10  ~g of GT  as  GT-MBSA in  M/P,  i.p.  7 days later,  the 
specific IgG PFC  per spleen were enumerated. The results from three experiments (12 
mice per group)  are expressed as arithmetic mean of PFC per spleen  -+  standard error 
(bars). P  value calculated according to Student's t test. 
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FIG.  2.  In vivo effects of anti-I-J' antiserum on the transfer of BAT-specific suppression 
in SJL (H-2') mice. Groups of mice (three mice per group) were primed on day 0 with 10 pg 
of BAT in Maalox or with Maalox alone, i.p. One group of mice (III) received on days 0,  1, 
and 2, 0.25 ml of HBSS i.v., and another group of mice (IV) received in the same manner 
10/~1 of [B10.A(3R)  x  B10.S(9R)]F1  anti-B10.HTT antiserum (anti-I-J') diluted in 0.25 ml 
of HBSS. On day 3, 10  x  106 viable spleen cells from each group were transferred i.v. into 
normal recipients (four per group) which were immediately challenged with 10/zg of GAT 
as GAT-MBSA in M/P, i.p. 7 days later the specific IgG PFC per spleen were enumerated. 
The results from two experiments (8 mice per group) are expressed as arithmetic mean of 
PFC per spleen _+  standard error (bars). P  values calculated according to the Student's t 
test. 662  IN  VIVO  ELIMINATION  OF  SUPPRESSION  BY  ANTI-I-J  SERA 
also observed with another anti-I-J  k antiserum,  B10.A(3R) anti-B10.A(5R), and 
in  SJL  mice  with  an  anti-I-J s  antiserum,  [B10.A(3R)  x  B10.S(gR)]F,  anti- 
B10.HTT.  This adjuvant  effect on anti-SRBC responses appears,  therefore,  to 
be  a  common  property  of such  anti-I-J  reagents,  and  represents  a  simple, 
convenient,  and  sensitive  method  for  testing  putative  anti-I-J  antisera  for 
activity.  The  ability  to  perform  the  assay  using  mice  not  congenic  at  the I 
region,  as required  in  the  MLR assay for I-J  activity reported  recently  (25), 
provides this method with certain advantages. 
The  fact  that  I-J  coded  determinants  have  to  date  been  considered  to  be 
expressed selectively on suppressor T cells and T-derived suppressor factors (1- 
5) raised  the  possibility that  the  potentiating  activity of these  sera could be 
related to an in vivo interference with these I-J-positive components of antigen- 
induced  specific  suppression.  The  observation  that  an  anti-I-J k  antiserum 
decreased tumor  growth  in  A/J  mice  inoculated  with  a  methylcholanthrene- 
induced fibrosarcoma (14) supported this possibility. In this model suppressor T 
cells play an important  role in regulating tumor growth (15,  16),  and prelimi- 
nary experiments indicated that anti-I-J k antiserum treatment reduces suppres- 
sor cell  activity in tumor-bearing  mice.  The  GT  or GAT-specific suppression 
characterizing  some  nonresponder  strains,  such  as  CBA  for  GT  or  SJL  for 
GAT, was, therefore, an appropriate model for testing the hypothesis that anti- 
I-J antisera mediated potentiation of immunity is due to reduction of suppressor 
T-cell responses. In a  first series of experiments,  it was established that  10 ~l 
of anti-I-J k antiserum  per day for 3 days allowed CBA mice to respond to GT, 
an antigen toward which this strain normally develops strong specific suppres- 
sion.  Similarly,  responsiveness to GAT was observed after treatment with an 
anti-I-J s antiserum,  in the SJL strain.  The earlier observation that responsive- 
ness to GT could be induced in BALB/c by cyclophosphamide (23) appears very 
similar to these results.  It is, therefore, reasonable to assume that the anti-I-J 
antisera acts similarly to cyclophosphamide, preventing in vivo development of 
efficient T-cell-mediated  suppression,  thus  permitting  GAT  or  GT-specific T 
helper cells to differentiate and/or to act (26). The second series of experiments 
strengthened this interpretation by establishing that in vivo anti-I-J antiserum 
treatment  prevents the  development of detectable antigen-specific  suppressor 
cells  in  GT-primed  CBA  mice  or  GAT-primed  SJL  mice,  as  assessed by an 
adoptive transfer protocol. However, since both helper and suppressor activity 
can  be  identified  in  nonresponder  strains  (23,  27),  it  cannot  be  definitively 
excluded  at  this  time  that  the  anti-I-J  antisera  does not  provide  a  positive 
inductive signal to I-J-bearing helper T cells, which are then able to act despite 
the  presence  of the  usually  predominant  suppressor  cells.  Support  for  this 
possibility,  however,  awaits  clear  demonstration  of the presence of I-J-coded 
products on helper cells,  particularly  for the antigens  GAT and  GT.  At least 
one "helper" factor for GT is known to carry I-A,  and not I-J subregion coded 
determinants,  but the presence of I-J coded antigens on other helper factors or 
on helper cells for either antigen has not been excluded at present. 
The effects of the  anti-I-J  antisera  appear to be specific, since:  (a)  anti-I-J ~ 
antiserum  does not induce  responsiveness to  GT in  CBA  (I-J  k)  mice;  and  (b) 
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suppression in CBA  (I-J  k) mice. However,  absorption experiments have not 
been performed to prove directly  that the effects  observed were related to anti- 
I-J antibodies contained in these sera. One can infer,  however, from such 
absorptions performed in previous studies,  that antibodies to I-J region deter- 
minants are the active  material in these reagents (13,  14). 
The  conversion by anti-I-J sera of nonresponder  mice to responders,  as 
demonstrated above, suggests the presence in nonresponder mice of  helper T- 
cell  precursors capable of  responding to GAT  or GT presented by conventional 
routes of immunization.  This further implies that it is the net balance of 
(helper  and suppressor) regulatory T-cell  responses  rather  than absolute defects 
in one or the other pathway which determines whether or not immunity is 
seen after  challenge with GAT or GT in suppressor nonresponder strains.  Such 
a hypothesis predicts  that transfer of  lymphocytes from anti-I-J-treated,  anti- 
gen-primed (GAT or GT) nonresponder mice into  normal syngeneic recipients 
might yield  detectable helper activity  able to more than counterbalance the 
usual suppressor response to a  GAT  or GT  challenge  in such recipients. 
Preliminary evidence indicates that this  can, in fact,  be observed in the GT 
system (M. Pierres,  unpublished observations). 
Finally, it is becoming  clear that I-J subregion-coded determinants  are 
present on both suppressor cells  and suppressor factors  (1-5), and that the 
pathway from antigen to final suppressive action requires at least two distinct 
suppressor T  cells and a  minimum of one factor which mediates interaction 
between these two T cells (28, 29). Tl~e suppressor factor and the T suppressor 
cell that it induces have already been typed as I-J positive  (2,  4), 3  and it is 
likely that the factor-producing T  cell is an I-J-bearing cell also.  This raises 
questions as to the site(s) of action of in vivo administered anti-I-J antisera, 
and studies are currently underway to independently assess potential anti-I-J 
activity on each of the known steps in the suppressor and helper pathways. 
Summary 
The in vivo effects  of  intravenous administration of  alloantisera  directed  to  l- 
J subregion coded determinants were investigated.  In confirmation and exten- 
sion of  our previous results,  anti-I-J  k [B10.A(3R) anti-B10.A(5R)] and anti-I-J  s 
([B10.A(3R) x B10.S(9R)]Fx anti-B10.HTT) antisera,  when administered in I  to 
10 pl amounts at  the time of  immunization, led  to twofold increases in  the IgM 
and IgG plaque-forming cells (PFC) responses to suboptimal doses of sheep 
erythrocytes in A/J (I-J  k) and SJL (I-J  s) mice, respectively.  To assess whether 
this  immunopotentiation was due to a decrease in specific  suppression, experi- 
ments were carried out using the polypeptide antigens random linear terpoly- 
mer of  L-glutamic acid  s°,  L-alanine  3°,  and L-tyrosine  x°  (GAT) and random linear 
copolymer of L-glutamic acidS°-L-tyrosine  5° (GT), since  administration of GAT 
to the nonresponder strain SJL, or GT to the nonresponder strain CBA  fails  to 
induce a primary PFC response and stimulates specific  suppressor T cells  able 
to prevent PFC responses to subsequent challenge with the immunogens GAT- 
rnethylated bovine serum albumin  (MBSA)  or GT-MBSA,  respectively.  The 
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current study demonstrates that CBA (I-J  k) mice given 100 ~g GT in Maalox- 
pertussis adjuvant on day 0, and 10 ~1 anti-I-J k antiserum i.v. on days 0, 1, and 
2,  develop  a  significant  primary  specific  PFC  response  on  day  7.  A  similar 
responsiveness to 10 ~g GAT is found in SJL mice treated with 10 ~1 anti-I-J  s 
antiserum  for 3  days.  This  same  active  anti-I-J  s antiserum  does  not  permit 
CBA mice to respond to GT, demonstrating the specificity of the anti-I-J effect. 
These data suggest that anti-I-J antiserum treatment at the time of antigen 
administration reduces suppressor responses to GAT or GT, permitting primary 
PFC responses.  To directly demonstrate such an effect on suppressor activity, 
SJL or CBA mice treated, respectively, with GAT or GT to induce suppressor 
cells active on GAT-MBSA or GT-MBSA responses  al~er adoptive transfer to 
normal syngeneic recipients were also given anti-LJ antisera  (10 ~l/day) for 3 
days, at which time their spleen cells were tested for suppressive activity upon 
transfer.  Cells  from  such  treated  mice  failed to  show  detectable  suppressive 
activity upon transfer to syngeneic recipients challenged with  GAT-MBSA or 
GT-MBSA, confirming the hypothesis of an in vivo effect of anti-I-J antiserum 
on suppressor activity. 
The authors thank Mrs. Sharon Smith for  her help in preparing this  manuscript. 
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